Propranolol hydrochloride injection from a subsidiary of China Resources Shuanghe (600062.SH) passed the generic drug consistency evaluation

Zhitongcaijing · 2d ago

Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, China Resources Zizhu Pharmaceutical Co., Ltd. (“China Resources Zizhu”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for propranolol hydrochloride injections issued by the State Drug Administration. After review, a supplementary application for adding the 2ml:2mg specification to this product was approved, and a drug approval number was issued. This product passed the consistent evaluation of the quality and efficacy of generic drugs.

This drug is suitable for: 1. Control ventricular tachyarrhythmias, ventricular arrhythmias, especially arrhythmias related to catecholamines or caused by digitalis. It can be used to control ventricular rate of atrial flutter and atrial fibrillation where the curative effect of digitalis is poor, and can also be used for intractable pre-period contractions to improve patients' symptoms. 2. Work-type angina pectoris. 3. Pheochromocytoma, used in combination with alpha blockers to control tachycardia.